

GABA Receptor Antagonists – Pipeline Insight, 2020

<https://marketpublishers.com/r/G14193F6A24EN.html>

Date: November 2020

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G14193F6A24EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "GABA Receptor Antagonists – Pipeline Insight, 2020," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in GABA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

GABA Receptor Antagonists Understanding

GABA Receptor Antagonists: Overview

Gamma-aminobutyric acid (GABA) inhibitors, or GABA antagonists, are drugs which inhibit the action of GABA, the primary inhibitory neurotransmitter of the central nervous system. They predominantly work at the GABA receptor. GABA receptors categorize into the GABA-A receptor and GABA-B receptor subtypes. There also exists a GABA-C receptor, but it is typically classified as a subtype of GABA-A receptors and named GABA-A-rho. While GABA-A receptors are ionotropic receptors that gate chloride channels, GABA-B receptors are metabotropic G-protein coupled receptors. The receptor subtypes can also be differentiated based on their selectivity to agonists and antagonists: GABA-A receptors are antagonized by bicuculline and insensitive to baclofen, whereas GABA-B receptors are agonized by baclofen and insensitive to

bicuculline. The potency of most GABA-A receptor antagonists is mostly independent of receptors subunit composition, in contrast to GABA-A receptor agonists.

Examples of GABA-A receptor antagonists include flumazenil, bicuculline, picrotoxin/picrotoxinin, gabazine, suramin, sepranolone, salicylidene salicylhydrazide (SCS), bilobalide, RU5135, and 4-(3-biphenyl-5-(4-piperidyl)-3-isoxazole (3-biphenyl-4-PIOL). Examples of GABA-C receptor antagonists include 1,2,5,6-Tetrahydropyridin-4-methylphosphinic acid (TPMPA).

GABA receptor antagonists produce convulsant and stimulant effects and mainly have a use for research purposes. For example, bicuculline and gabazine are frequently used to dissect GABA-A receptor components in neurons functionally. These GABA receptor antagonists act as subtype-selective compounds and help to study the behavioral effects of the different GABA-A receptor subtypes.

The major inhibitory neurotransmitter in the central nervous system (CNS) is the gamma-aminobutyric acid (GABA). Inhibition is mediated by the ionotropic and metabotropic receptors, located pre or postsynaptically.

GABA Receptor Antagonists Emerging Drugs Chapters

This segment of the GABA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

GABA Receptor Antagonists Emerging Drugs

Golexanolone: Umecrine Cognition

Golexanolone, also known by the developmental code name GR-3027, is a neurosteroid medication which is under development for the treatment of hypersomnia and hepatic encephalopathy. It acts as a negative allosteric modulator of the GABAA receptor.

Further product details are provided in the report.....

GABA Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different GABA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on GABA Receptor Antagonists

There are approx. 15+ key companies which are developing the GABA Receptor Antagonists. The companies which have their GABA Receptor Antagonists drug candidates in the most advanced stage, i.e. phase II include, Umechrine Cognition.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

GABA Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

GABA Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses GABA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA Receptor Antagonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for GABA Receptor Antagonists.

February 2020: Cerecor announced it had completed the previously announced acquisition of Aevi Genomic Medicine in an all-stock transaction valued at approximately USD 15.6 million at close, plus contingent value rights (CVRs) for up to an additional USD 6.5 million in subsequent payments based on clinical and/or regulatory milestones. Cerecor's pipeline now includes six clinical-stage assets, accelerating the Company's transformation into a research and development organization focused on developing new medicines for unmet needs in rare diseases, particularly for pediatric patients. The Company continues to explore strategic alternatives for its non-core neurological assets, including CERC-301, as well as its sole commercialized product, Millipred.

GABA Receptor Antagonists Report Insights

GABA Receptor Antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

GABA Receptor Antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing GABA Receptor Antagonists drugs?

How many GABA Receptor Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for GABA Receptor Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for GABA Receptor Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

Servier

Umecrine Cognition

Angelini

Key Products

SGS 742

Afizagabar

Golexanolone

Gabapentin/trazodone hydrochloride

Contents

Introduction

Executive Summary

GABA Receptor Antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

GABA Receptor Antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

GABA Receptor Antagonists companies' collaborations, Licensing, Acquisition -Deal Value Trends

GABA Receptor Antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Golexanolone: Umeocrine Cognition

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

GABA Receptor Antagonists Key Companies

GABA Receptor Antagonists Key Products

GABA Receptor Antagonists- Unmet Needs

GABA Receptor Antagonists- Market Drivers and Barriers

GABA Receptor Antagonists- Future Perspectives and Conclusion

GABA Receptor Antagonists Analyst Views

GABA Receptor Antagonists Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for GABA Receptor Antagonists
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for GABA Receptor Antagonists
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: GABA Receptor Antagonists – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/G14193F6A24EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G14193F6A24EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970